Epithelial Ovarian Cancer-an Audit of Patients Treated Over 15 Years

Punita Lal; Anu Tiwari; Neeraj Rastogi; Shaleen Kumar

doi:10.1055/s-0041-1733145

Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2006; 27(01): 15-22
DOI: 10.1055/s-0041-1733145

Original Article

Epithelial Ovarian Cancer-an Audit of Patients Treated Over 15 Years

Punita Lal

Department of Radiotherapy, Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow 226014, India

,

Anu Tiwari

Department of Radiotherapy, Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow 226014, India

,

Neeraj Rastogi

Department of Radiotherapy, Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow 226014, India

,

Shaleen Kumar

Department of Radiotherapy, Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow 226014, India

› Institutsangaben

Abstract

als PDF herunterladen

PDF (213 kb)

Referenzen

References
1 Ovarian Cancer Meta-analysis Project: Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma. J Clin Oncol 1991;9:1668-1674.
2 Gruppo Interregionale Cooperativo Oncologico Ginecologia: Randomized comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/ doxorubicin/cisplatin in advanced ovarian cancer. Lancet 1987;2:353-359.
3 Mc Guire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996;334:1-6.
4 ICON Group. ICON 2: Randomized trial of single agent carboplatin against 3 drug combination of CAP (cyclophosphamide, adriamycin, cisplatin) in women with ovarian cancer. Lancet 1998;352:1571-76
5 ICON Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide, doxorubicin and cisplatin in women with ovarian cancer: the ICON 3 randomized trial. Lancet 2002;360:505-515.
6 James .D. Cox, Jo ANN Stetz, B.S., et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and The European Organization for Research and Treatment of Cancer (EORTC). Int.J.Rad Oncol Biol, Phys 1995:31(5),1341-1346.
7 Ansquer Y, Leblanc E, Clough K, et al. Neoadjuvant chemotherapy for unresectable ovarian carcinomaa French multicenter study. Cancer 2001;91:2329-34.
8 Thigpen T. The if and when of surgical debulking for ovarian carcinoma. N Engl J Med 2004;351:2544-2546.
9 A'Hern RP and Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995;13(3): 726-732.
10 Muggla FM, Braly PS. Brady MF, et al. Phase III randomized study of eisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV overian cancer: A Gynecologic Oncology Group study J Clin Oncol 2000;18:106-115.
11 Advanced Ovarian Cancer Trialists Group: Chemotherapy in advanced ovarian cancer: An overview of randomized clinical trials. Br Med J 1991;303:884-893.
12 Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-3200.
13 Sandercock J, Parmar MKB, Torri V. First line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence. Br J Cancer 1998;78(11):1471-1478.
14 Buyse M, Burzykowski T, Parmar M, et al. J. Using the expected survival to explain differences between the results of randomized trials: A case in advanced ovarian cancer. J Clin Oncol. 2003:21;1682-1687.
15 Charak BS, Agarwala S, Gopal R, et al. Cisplatin based chemotherapy in advanced ovarian carcinoma: initial experience in an Indian setup. Ind J Cancer. 1989;26(2):85-91.
16 Yeole BB, Kumar AV, Kurkure A and Sunny L. Population based survival from cancers of breast cervix and ovary in women in Mumbai, India. Asian Pac J Cancer Prev. 2004;5(3):308-15.
17 Van der Burg, Lent MV, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Eng J Med 2004;332:629-634.